ID   LYN_HUMAN               Reviewed;         512 AA.
AC   P07948; A0AVQ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   05-OCT-2010, entry version 142.
DE   RecName: Full=Tyrosine-protein kinase Lyn;
DE            EC=2.7.10.2;
GN   Name=LYN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=87172710; PubMed=3561390;
RA   Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N.,
RA   Matsubara K., Yamamoto T., Toyoshima K.;
RT   "The yes-related cellular gene lyn encodes a possible tyrosine kinase
RT   similar to p56lck.";
RL   Mol. Cell. Biol. 7:237-243(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94171041; PubMed=8125304; DOI=10.1016/0378-1119(94)90811-7;
RA   Rider L.G., Raben N., Miller L., Jelsema C.;
RT   "The cDNAs encoding two forms of the LYN protein tyrosine kinase are
RT   expressed in rat mast cells and human myeloid cells.";
RL   Gene 138:219-222(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LYN A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   MEDLINE=91062389; PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-424.
RX   MEDLINE=92378604; PubMed=1510669; DOI=10.1016/S0006-291X(05)81562-1;
RA   Bielke W., Ziemiecki A., Kappos L., Miescher G.C.;
RT   "Expression of the B cell-associated tyrosine kinase gene Lyn in
RT   primary neuroblastoma tumours and its modulation during the
RT   differentiation of neuroblastoma cell lines.";
RL   Biochem. Biophys. Res. Commun. 186:1403-1409(1992).
RN   [6]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A.
RX   PubMed=7895172; DOI=10.1016/S1074-7613(95)80040-9;
RA   Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R.,
RA   Bolen J.B., Kieff E.;
RT   "Integral membrane protein 2 of Epstein-Barr virus regulates
RT   reactivation from latency through dominant negative effects on
RT   protein-tyrosine kinases.";
RL   Immunity 2:155-166(1995).
RN   [7]
RP   INTERACTION WITH PDE4A.
RC   TISSUE=Brain;
RX   MEDLINE=21203792; PubMed=11306681;
RA   Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L.,
RA   Huston E., Sullivan M., Houslay M.D.;
RT   "Molecular cloning, genomic positioning, promoter identification, and
RT   characterization of the novel cyclic AMP-specific phosphodiesterase
RT   PDE4A10.";
RL   Mol. Pharmacol. 59:996-1011(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=10891478; DOI=10.1128/MCB.20.15.5370-5380.2000;
RA   Yoshida K., Weichselbaum R., Kharbanda S., Kufe D.;
RT   "Role for Lyn tyrosine kinase as a regulator of stress-activated
RT   protein kinase activity in response to DNA damage.";
RL   Mol. Cell. Biol. 20:5370-5380(2000).
RN   [9]
RP   INTERACTION WITH PPP1R15A.
RX   PubMed=11517336; DOI=10.1073/pnas.191130798;
RA   Grishin A.V., Azhipa O., Semenov I., Corey S.J.;
RT   "Interaction between growth arrest-DNA damage protein 34 and Src
RT   kinase Lyn negatively regulates genotoxic apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10172-10177(2001).
RN   [10]
RP   INTERACTION WITH MUC1.
RX   PubMed=12750561;
RA   Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.;
RT   "DF3/MUC1 signaling in multiple myeloma cells is regulated by
RT   interleukin-7.";
RL   Cancer Biol. Ther. 2:187-193(2003).
RN   [11]
RP   SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF LYS-275; ASP-346;
RP   GLU-353; ASP-498 AND ASP-499.
RX   PubMed=15173188; DOI=10.1083/jcb.200403011;
RA   Kasahara K., Nakayama Y., Ikeda K., Fukushima Y., Matsuda D.,
RA   Horimoto S., Yamaguchi N.;
RT   "Trafficking of Lyn through the Golgi caveolin involves the charged
RT   residues on alphaE and alphaI helices in the kinase domain.";
RL   J. Cell Biol. 165:641-652(2004).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-508, AND MASS
RP   SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=16467205; DOI=10.1182/blood-2005-08-3343;
RA   Nakata Y., Tomkowicz B., Gewirtz A.M., Ptasznik A.;
RT   "Integrin inhibition through Lyn-dependent cross talk from CXCR4
RT   chemokine receptors in normal human CD34+ marrow cells.";
RL   Blood 107:4234-4239(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND TYR-508, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=17233630; DOI=10.1042/BJ20061618;
RA   Rathore V.B., Okada M., Newman P.J., Newman D.K.;
RT   "Paxillin family members function as Csk-binding proteins that
RT   regulate Lyn activity in human and murine platelets.";
RL   Biochem. J. 403:275-281(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-193; TYR-194; TYR-306;
RP   TYR-397; TYR-473 AND TYR-508, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-316, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=19007248; DOI=10.1021/ac801708p;
RA   Wang B., Malik R., Nigg E.A., Korner R.;
RT   "Evaluation of the low-specificity protease elastase for large-scale
RT   phosphoproteome analysis.";
RL   Anal. Chem. 80:9526-9533(2008).
RN   [20]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLY-2; CYS-3 AND LYS-275.
RX   PubMed=18817770; DOI=10.1016/j.yexcr.2008.08.019;
RA   Ikeda K., Nakayama Y., Togashi Y., Obata Y., Kuga T., Kasahara K.,
RA   Fukumoto Y., Yamaguchi N.;
RT   "Nuclear localization of Lyn tyrosine kinase mediated by inhibition of
RT   its kinase activity.";
RL   Exp. Cell Res. 314:3392-3404(2008).
RN   [21]
RP   FUNCTION.
RX   PubMed=18802065;
RA   Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G.,
RA   Ptasznik A.;
RT   "Monocyte migration and LFA-1-mediated attachment to brain
RT   microvascular endothelia is regulated by SDF-1 alpha through Lyn
RT   kinase.";
RL   J. Immunol. 181:4632-4637(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13 AND TYR-397, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; TYR-32;
RP   TYR-194; SER-228; TYR-397; TYR-473 AND TYR-508, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with
RT   cellular SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-193; TYR-397 AND
RP   TYR-508, AND MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; SER-11; SER-13;
RP   THR-30; TYR-32; THR-37; TYR-193; TYR-194; SER-228; TYR-265; TYR-306;
RP   TYR-316; TYR-473; THR-489; THR-502 AND TYR-508, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   INTERACTION WITH NDFIP1 AND NDFIP2, AND UBIQUITINATION.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the
RT   ubiquitin ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [29]
RP   STRUCTURE BY NMR OF 61-123 IN COMPLEX WITH HERPESVIRUS SAIMIRI
RP   TYROSINE KINASE INTERACTING PROTEIN.
RX   PubMed=11955060; DOI=10.1021/bi015986j;
RA   Schweimer K., Hoffmann S., Bauer F., Friedrich U., Kardinal C.,
RA   Feller S.M., Biesinger B., Sticht H.;
RT   "Structural investigation of the binding of a herpesviral protein to
RT   the SH3 domain of tyrosine kinase Lck.";
RL   Biochemistry 41:5120-5130(2002).
RN   [30]
RP   STRUCTURE BY NMR OF 61-122 IN COMPLEX WITH HERPESVIRUS TYROSINE KINASE
RP   INTERACTING PROTEIN.
RX   PubMed=16155203; DOI=10.1110/ps.051563605;
RA   Bauer F., Schweimer K., Meiselbach H., Hoffmann S., Rosch P.,
RA   Sticht H.;
RT   "Structural characterization of Lyn-SH3 domain in complex with a
RT   herpesviral protein reveals an extended recognition motif that
RT   enhances binding affinity.";
RL   Protein Sci. 14:2487-2498(2005).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-512 IN COMPLEX WITH
RP   STAUROSPORINE.
RX   PubMed=19857964; DOI=10.1016/j.bmcl.2009.10.038;
RA   Miyano N., Kinoshita T., Nakai R., Kirii Y., Yokota K., Tada T.;
RT   "Structural basis for the inhibitor recognition of human Lyn kinase
RT   domain.";
RL   Bioorg. Med. Chem. Lett. 19:6557-6560(2009).
RN   [32]
RP   VARIANT [LARGE SCALE ANALYSIS] TYR-385.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Down regulates expression of stem cell growth factor
CC       receptor (KIT). Acts as an effector of EpoR (erythropoietin
CC       receptor) in controlling KIT expression and may play a central
CC       role in erythroid differentiation during the switch between
CC       proliferation and maturation (By similarity). Acts as a positive
CC       regulator of cell movement while negatively regulating adhesion to
CC       stromal cells by inhibiting the ICAM-1-binding activity of beta-2
CC       integrins. Acts as the mediator that relays suppressing signals
CC       from the chemokine receptor CXCR4 to beta-2 integrin LFA-1 in
CC       hematopoietic precursors. Involved in induction of stress-
CC       activated protein kinase (SAPK), but not ERK or p38 MAPK, in
CC       response to genotoxic agents. Induces SAPK by a MKK7- and MEKK1-
CC       dependent mechanism. The LYN -> MEKK1 -> MKK7 -> SAPK pathway is
CC       functional in the induction of apoptosis by genotoxic agents.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with phosphorylated LIME1 and with CD79A upon
CC       BCR activation. Interacts with Epstein-Barr virus LMP2A. Interacts
CC       with TGFB1I1. Interaction, via the SH2 and SH3, domains with MUC1
CC       is stimulated by IL7 and, the subsequent phosphorylation increases
CC       the binding between MUC1 and CTNNB1/beta-catenin. Interacts with
CC       PPP1R15A and PDE4A via the SH3 domain. Interacts with Herpesvirus
CC       saimiri tyrosine kinase interacting protein (Tip). Interacts with
CC       ADAM15. Interacts with NDFIP2 and more weakly with NDFIP1.
CC       Interacts with phosphorylated THEMIS2 (By similarity).
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-79452, EBI-710506;
CC       P26660:- (xeno); NbExp=1; IntAct=EBI-79452, EBI-706322;
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-79452, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=2; IntAct=EBI-79452, EBI-710918;
CC       Q8R5G7:Arap3 (xeno); NbExp=2; IntAct=EBI-79452, EBI-621463;
CC       Q9QWY8:Asap1 (xeno); NbExp=2; IntAct=EBI-79452, EBI-698498;
CC       P20273:CD22; NbExp=1; IntAct=EBI-79452, EBI-78277;
CC       P11802:CDK4; NbExp=1; IntAct=EBI-79452, EBI-295644;
CC       P46527:CDKN1B; NbExp=2; IntAct=EBI-79452, EBI-519280;
CC       P67870:CSNK2B; NbExp=1; IntAct=EBI-79452, EBI-348169;
CC       P48023:FASLG; NbExp=1; IntAct=EBI-79452, EBI-495538;
CC       Q9HCN6:GP6; NbExp=2; IntAct=EBI-79452, EBI-515278;
CC       P05556:ITGB1; NbExp=1; IntAct=EBI-79452, EBI-703066;
CC       Q07666:KHDRBS1; NbExp=1; IntAct=EBI-79452, EBI-1364;
CC       Q8CI15:Sphk1 (xeno); NbExp=1; IntAct=EBI-79452, EBI-985291;
CC       Q9NRA0:SPHK2; NbExp=1; IntAct=EBI-79452, EBI-985324;
CC       Q9JIA7:Sphk2 (xeno); NbExp=1; IntAct=EBI-79452, EBI-985434;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Nucleus. Cytoplasm.
CC       Cytoplasm, perinuclear region. Golgi apparatus. Note=Accumulates
CC       in the nucleus by inhibition of CRM1-mediated nuclear export.
CC       Nuclear accumulation is increased by inhibition of its kinase
CC       activity. The trafficking from the Golgi apparatus to the plasma
CC       membrane occurs in a kinase domain-dependent but kinase activity
CC       independent manner and is mediated by exocytic vesicular
CC       transport.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=LYN A;
CC         IsoId=P07948-1; Sequence=Displayed;
CC       Name=LYN B;
CC         IsoId=P07948-2; Sequence=VSP_005002;
CC   -!- TISSUE SPECIFICITY: Widely expressed in a variety of organs,
CC       tissues, and cell types such as epidermoid, hematopoietic, and
CC       neuronal cells. Expressed in primary neuroblastoma tumors.
CC   -!- DOMAIN: The protein kinase domain plays an important role in its
CC       localization in the cell membrane.
CC   -!- PTM: Ubiquitinated. Ubiquitination is SH3-dependent.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16038; AAA59540.1; -; mRNA.
DR   EMBL; M79321; AAB50019.1; -; mRNA.
DR   EMBL; BC075001; AAH75001.1; -; mRNA.
DR   EMBL; BC075002; AAH75002.1; -; mRNA.
DR   EMBL; BC126456; AAI26457.1; -; mRNA.
DR   EMBL; BC126458; AAI26459.1; -; mRNA.
DR   IPI; IPI00298625; -.
DR   IPI; IPI00432416; -.
DR   PIR; A26719; TVHULY.
DR   RefSeq; NP_001104567.1; -.
DR   RefSeq; NP_002341.1; -.
DR   UniGene; Hs.491767; -.
DR   PDB; 1W1F; NMR; -; A=61-122.
DR   PDB; 1WA7; NMR; -; A=61-123.
DR   PDB; 3A4O; X-ray; 3.00 A; X=233-512.
DR   PDBsum; 1W1F; -.
DR   PDBsum; 1WA7; -.
DR   PDBsum; 3A4O; -.
DR   ProteinModelPortal; P07948; -.
DR   SMR; P07948; 67-512.
DR   DIP; DIP-1056N; -.
DR   IntAct; P07948; 49.
DR   MINT; MINT-200655; -.
DR   STRING; P07948; -.
DR   PhosphoSite; P07948; -.
DR   REPRODUCTION-2DPAGE; P07948; -.
DR   PRIDE; P07948; -.
DR   Ensembl; ENST00000502902; ENSP00000421267; ENSG00000249529.
DR   GeneID; 4067; -.
DR   KEGG; hsa:4067; -.
DR   UCSC; uc003xsk.2; human.
DR   UCSC; uc003xsl.2; human.
DR   CTD; 4067; -.
DR   GeneCards; GC08P056792; -.
DR   H-InvDB; HIX0025560; -.
DR   HGNC; HGNC:6735; LYN.
DR   HPA; CAB004492; -.
DR   HPA; HPA001231; -.
DR   MIM; 165120; gene.
DR   PharmGKB; PA30498; -.
DR   eggNOG; prNOG04075; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG008761; -.
DR   OMA; WMGYYNN; -.
DR   OrthoDB; EOG9BZQMQ; -.
DR   PhylomeDB; P07948; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; alphasynuclein_pathway; Alpha-synuclein signaling.
DR   Pathway_Interaction_DB; amb2_neutrophils_pathway; amb2 Integrin signaling.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epha_fwdpathway; EPHA forward signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; epopathway; EPO signaling pathway.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 15944; -.
DR   PMAP-CutDB; P07948; -.
DR   ArrayExpress; P07948; -.
DR   Bgee; P07948; -.
DR   CleanEx; HS_LYN; -.
DR   Genevestigator; P07948; -.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; TAS:ProtInc.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IEA:InterPro.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0051272; P:positive regulation of cellular component m...; IDA:UniProtKB.
DR   GO; GO:0070304; P:positive regulation of stress-activated pro...; IDA:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphoryla...; ISS:UniProtKB.
DR   GO; GO:0006974; P:response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0009725; P:response to hormone stimulus; ISS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020747; Tyr_kinase_non-rcpt_Lyn.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF258; Tyr_kinase_non-rcpt_Lyn; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Golgi apparatus; Host-virus interaction;
KW   Kinase; Lipoprotein; Membrane; Myristate; Nucleotide-binding; Nucleus;
KW   Palmitate; Phosphoprotein; Polymorphism; Proto-oncogene; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    512       Tyrosine-protein kinase Lyn.
FT                                /FTId=PRO_0000088129.
FT   DOMAIN       63    123       SH3.
FT   DOMAIN      129    226       SH2.
FT   DOMAIN      247    501       Protein kinase.
FT   NP_BIND     253    261       ATP (By similarity).
FT   ACT_SITE    367    367       Proton acceptor (By similarity).
FT   BINDING     275    275       ATP (By similarity).
FT   MOD_RES       6      6       Phosphoserine.
FT   MOD_RES      11     11       Phosphoserine.
FT   MOD_RES      13     13       Phosphoserine.
FT   MOD_RES      30     30       Phosphothreonine.
FT   MOD_RES      32     32       Phosphotyrosine.
FT   MOD_RES      37     37       Phosphothreonine.
FT   MOD_RES     193    193       Phosphotyrosine.
FT   MOD_RES     194    194       Phosphotyrosine.
FT   MOD_RES     228    228       Phosphoserine.
FT   MOD_RES     265    265       Phosphotyrosine.
FT   MOD_RES     306    306       Phosphotyrosine.
FT   MOD_RES     316    316       Phosphotyrosine.
FT   MOD_RES     397    397       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     473    473       Phosphotyrosine.
FT   MOD_RES     489    489       Phosphothreonine.
FT   MOD_RES     502    502       Phosphothreonine.
FT   MOD_RES     508    508       Phosphotyrosine.
FT   LIPID         2      2       N-myristoyl glycine (By similarity).
FT   LIPID         3      3       S-palmitoyl cysteine (By similarity).
FT   VAR_SEQ      23     43       Missing (in isoform LYN B).
FT                                /FTId=VSP_005002.
FT   VARIANT     385    385       D -> Y (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041737.
FT   MUTAGEN       2      2       G->A: Loss of localization to the cell
FT                                membrane; when associated with A-3.
FT   MUTAGEN       3      3       C->A: Loss of localization to the cell
FT                                membrane; when associated with A-2.
FT   MUTAGEN     275    275       K->A: Loss of activity and no effect on
FT                                localization to the cell membrane.
FT                                Abundant localization in the nucleus;
FT                                when associated with A-2 and A-3.
FT   MUTAGEN     346    346       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-353; A-498 and A-
FT                                499.
FT   MUTAGEN     353    353       E->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-498 and A-
FT                                499.
FT   MUTAGEN     498    498       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-353 and A-
FT                                499.
FT   MUTAGEN     499    499       D->A: Impedes the trafficking from the
FT                                Golgi apparatus toward the cell membrane;
FT                                when associated with A-346; A-353 and A-
FT                                498.
FT   STRAND       66     72
FT   STRAND       78     80
FT   STRAND       89     95
FT   STRAND       97    104
FT   TURN        105    107
FT   STRAND      110    114
FT   TURN        115    117
FT   STRAND      118    120
SQ   SEQUENCE   512 AA;  58574 MW;  408D3D461204E378 CRC64;
     MGCIKSKGKD SLSDDGVDLK TQPVRNTERT IYVRDPTSNK QQRPVPESQL LPGQRFQTKD
     PEEQGDIVVA LYPYDGIHPD DLSFKKGEKM KVLEEHGEWW KAKSLLTKKE GFIPSNYVAK
     LNTLETEEWF FKDITRKDAE RQLLAPGNSA GAFLIRESET LKGSFSLSVR DFDPVHGDVI
     KHYKIRSLDN GGYYISPRIT FPCISDMIKH YQKQADGLCR RLEKACISPK PQKPWDKDAW
     EIPRESIKLV KRLGAGQFGE VWMGYYNNST KVAVKTLKPG TMSVQAFLEE ANLMKTLQHD
     KLVRLYAVVT REEPIYIITE YMAKGSLLDF LKSDEGGKVL LPKLIDFSAQ IAEGMAYIER
     KNYIHRDLRA ANVLVSESLM CKIADFGLAR VIEDNEYTAR EGAKFPIKWT APEAINFGCF
     TIKSDVWSFG ILLYEIVTYG KIPYPGRTNA DVMTALSQGY RMPRVENCPD ELYDIMKMCW
     KEKAEERPTF DYLQSVLDDF YTATEGQYQQ QP
//
